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Abstract 59 
Purpose: We explored the interaction between non-Hodgkin lymphoma (NHL), 60 
infectious mononucleosis (IM) history, and immune-related genotypes in a pooled case-61 
control analysis.  62 
Methods: 7926 NHL patients and 10018 controls from 12 case-control studies were 63 
included. Studies were conducted during various time periods between 1988 and 2008, 64 
and participants were 17-96 years of age at the time of ascertainment/recruitment. Self-65 
reported IM history and immune response genotypes were provided by the InterLymph 66 
Data Coordinating Center at Mayo Clinic. Odds ratios (OR) were estimated using 67 
multivariate logistic regression, and interactions were estimated using the empirical 68 





Results: There was evidence of an interaction effect between IM history and two 70 
variants on T-cell lymphoma (TCL) risk: rs1143627 in interleukin-1B (pinteraction=0.04, 71 
ORinteraction=0.09, 95% confidence interval [CI]=0.01, 0.87) and rs1800797 in interleukin-6 72 
(pinteraction=0.03, ORinteraction=0.08, 95% CI=0.01, 0.80). Neither interaction effect withstood 73 
adjustment for multiple comparisons. There were no statistically significant interactions 74 
between immune response genotypes and IM on other NHL subtypes.  75 
Conclusions: Genetic risk variants in IL1B and IL6 may affect the association between 76 
IM and TCL, possibly by influencing T-cell activation, growth, and differentiation in the 77 
presence of IM, thereby decreasing risk of immune cell proliferation.  78 
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  119 
Introduction 120 
Non-Hodgkin lymphoma (NHL) comprises a group of lymphoid malignancies with 121 
distinct histopathologies and risk patterns originating from B- (~80%) and T-lymphocytes 122 
(~20%) [1]. Genetic or acquired immunodeficiency is the strongest risk factor, but more 123 
subtle immune alterations may also play a role in pathogenesis [2]. For example, there 124 
is a strong positive association between NHL and autoimmune disease [3, 4] and an 125 
inverse association with atopy [5]. In addition to evidence of familiality for overall and 126 
subtype-specific NHL risk [6, 7], variants in and near genes related to innate and 127 
adaptive immunity (IL1RN, FCGR2A, TNFA, HLA Class I and II) [8–10] have been 128 
implicated as potential risk factors. 129 
Several infectious agents, including Epstein-Barr virus (EBV) [11], Hepatitis C 130 
virus [12], and Helicobacter pylori [13], contribute to NHL etiology through various 131 
mechanisms including direct transformation of lymphocytes, immunosuppression, 132 
chronic B-cell activation, and innate immune stimulation [14]. EBV, a ubiquitous member 133 
of the human herpesvirus family, induces B-cell growth by expression of viral proteins 134 
and non-coding RNAs [15]. The viral DNA persists as an episome in the host memory B-135 
cell DNA after infection where it remains latent in the presence of a competent cytotoxic 136 
T-cell response. When acquired early in life, primary EBV infection is generally 137 
asymptomatic or causes a mild, non-specific, febrile illness [16]. In industrialized 138 
countries and populations of higher socioeconomic status (SES), primary infection is 139 
often delayed until adolescence or young adulthood. From 25% to 74% of those 140 





moderate to severe clinical syndrome characterized by fever, tonsillar pharyngitis, and 142 
lymphadenopathy [17–19]. The severity of primary EBV infection and the development 143 
of IM are attributable, at least in part, to an amplified EBV-specific CD8+, and to a lesser 144 
extent, CD4+ T-cell response which is not observed in those whose EBV seroconversion 145 
occurs asymptomatically [20–22]. Propensity to develop the syndrome is influenced by 146 
genetic factors related to immune response [23, 24]. 147 
In the largest pooled case-control study of NHL conducted to date from the 148 
International Lymphoma Epidemiology Consortium (InterLymph), Becker et al. (2012) 149 
observed a positive association between self-reported IM history and risk of all NHL 150 
(OR=1.26, 95% CI=1.01, 1.57). When stratified by subtype, associations were observed 151 
between IM and T-cell lymphoma (TCL) and a B-cell category combining chronic 152 
lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic 153 
lymphoma (PLL), and mantle cell lymphoma (MCL) [25]. Mechanisms for this 154 
association have not been explored. 155 
Studies indicating familial IM clustering and higher concordance for IM risk 156 
among monozygotic compared to dizygotic twin pairs suggest a role for genetic 157 
susceptibility in IM etiology [26, 27]. However, little is known about the influence of 158 
genetic factors on IM risk or their role in modifying the possible association between IM 159 
and NHL. Many of the genetic risk loci identified for NHL and NHL subtypes in previous 160 
InterLymph studies are in or near genes related to immune response that might also 161 
influence the association between IM and NHL risk [8, 9, 28–32].  162 
In this InterLymph study, we examined the joint effects of IM history and 12 163 







Study population 167 
Participants included NHL patients and controls contributed from case-control 168 
studies at InterLymph Consortium member sites. All 12 studies (from 10 countries) had 169 
approval from their respective National or Institutional Review Boards, and participants 170 
provided signed informed consent according to the WMA Declaration of Helsinki Ethical 171 
Principles for Medical Research Involving Human Subjects in 1964.  172 
Seven participating sites used population-based ascertainment (population-based 173 
case-control studies: British Columbia Cancer Agency BC, [Canada]; Scandinavian 174 
Lymphoma Etiology: SCALE [Denmark, Sweden]; University of California San Francisco: 175 
UCSF [USA]; National Cancer Institute Surveillance, Epidemiology, and End Results: 176 
NCI-SEER [USA]; Epilymph-Germany; Yale [USA]). Cases from these sites were 177 
ascertained from population-based cancer registries or national health systems, and 178 
controls were recruited from the same source population as the cases (census or 179 
random digit dialing rosters or from the same national health system clinic practice, 180 
respectively). 181 
 Five sites used clinic or hospital-based ascertainment (clinic-based case-control 182 
studies: Epilymph-Spain, Epilymph-France, Epilymph-Ireland, Epilymph-Czech Republic, 183 
Mayo Clinic). Patients at these sites were identified from clinic or hospital records and 184 
controls were identified from other patients without cancer attending the same clinics.  185 
Studies were conducted during various time periods between 1988 and 2008, 186 
and participants were 17-96 years of age at the time of ascertainment/recruitment. A 187 
summary of study details is provided in Supplemental Table 1 with additional details 188 





InterLymph Consortium member studies were selected for inclusion based on the 190 
availability of self-reported IM history and candidate variant genotypes from at least 50% 191 
of participants. Participants who had missing data for age at enrollment, sex, SES, or IM 192 
history were excluded. Because the number of non-white participants in member studies 193 
was small and would require stratification for genetic analyses, we limited the study to 194 
white participants. Consistent with previous InterLymph analyses, participants who 195 
reported IM diagnosis less than 2 years before NHL diagnosis were excluded [25]. 196 
 197 
Data collection 198 
The InterLymph Data Coordinating Center (Mayo Clinic, Rochester, MN) 199 
harmonized data submitted by each study site into a de-identified, pooled dataset for 200 
analysis. Information on demographics, family structure (number of siblings and birth 201 
order), and IM history was self-reported using questionnaires [1]. Ethnicity/race was 202 
available for eleven of the twelve study centers included in the analysis, with the 203 
participants from most of these European, U.S., and Canadian studies being non-204 
Hispanic white. Participants with missing race/ethnicity were included from SCALE 205 
(N=5683), Mayo Clinic (N=28), Yale (N=3), NCI-SEER-Seattle and Iowa (N=20) studies 206 
since the majority of the population in these study areas is non-Hispanic white; 207 
otherwise those with missing race were excluded. Socioeconomic status (SES) was 208 
categorized based on years of education (low: 0-12 years, high school or less; medium: 209 
13-15 years, some college; high: 16+ years, college degree or more) or tertiles of the 210 
SES variable submitted by each individual study center.  211 
The pooled analysis used existing genotype data on variants selected a priori 212 





/anti-inflammatory pathways [8, 9, 28–30]. The effects of these 12 genetic variants 214 
located in or near nine immune-response genes were assessed: IL1A-889C>T 215 
(rs1800587), IL1B–511C>T (rs16944), IL1B–31T>C (rs1143627), IL1RN–9589A>T 216 
(rs454078), IL2–384T>G (rs2069762), IL6–174G>C (rs1800795), IL6–597G>A 217 
(rs1800797), IL10–3575T>A (rs1800890), IL10–1082A>G (rs1800896), TNF–308G>A 218 
(rs1800629), HLA class I C>A (rs6457327), and HLA class II T>G (rs10484561). 219 
Genotyping was performed using either TaqMan (Applied Biosystems, Inc., Foster City, 220 
California), Pyrosequencing (Qiagen NV, Hilden, Germany), or Illumina Goldengate 221 
(Illumina, Inc., San Diego, California) genotyping assays. Additional technical details 222 
about genotyping methods used in each contributing study are included in previous 223 
publications [8, 29, 30, 33, 44].  224 
All NHL diagnoses were confirmed by pathology report review, with the majority 225 
re-reviewed by a hematopathologist, depending on the study. NHL subtypes were 226 
classified according to the World Health Organization (WHO) classification in 2001 and 227 
2008 [45–47] and include chronic lymphocytic leukemia/small lymphocytic lymphoma 228 
(CLL/SLL: ICD-O-3 codes 9670, 9823), diffuse large B-cell lymphoma (DLBCL: 9679, 229 
9680, 9684), follicular lymphoma (FL: 9690, 9691, 9695, 9698), mantle cell lymphoma 230 
(MCL: 9673), TCL (9702, 9705, 9708, 9709, 9714, 9716, 9717, 9718, 9719, 9729, 9827, 231 
9834), and all NHL combined (defined by the above ICDO3 codes and 9671, 9675, 232 
9687, 9689, 9699, 9700, 9701, 9728, 9826, 9832, 9833, 9591, and 9727). Patients with 233 
AIDS-related lymphomas were excluded. 234 
 235 





Candidate variants in linkage disequilibrium (LD): SNP Annotation and Proxy 237 
Search (SNAP) [48] was used to assess LD via correlations between all pairs of 238 
candidate variants in the same gene.  239 
Main effect NHL associations: Unconditional logistic regression was used to 240 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association 241 
between IM and NHL and for associations between candidate genetic variants and NHL. 242 
Consistent with other InterLymph publications [29, 30], all genetic variants were coded 243 
as dichotomous variables assuming a dominant model (absence or presence of minor 244 
allele). All models were adjusted for age at NHL diagnosis/enrollment, sex, study center, 245 
and SES.  246 
Gene-environment interaction in NHL risk: The effect of interaction between IM 247 
and immune-related genotypes on NHL risk was assessed using the empirical Bayes 248 
approach described by Mukherjee et al. [49]. Sensitivity analyses were then performed 249 
using unconditional logistic regression to test the association between IM and NHL 250 
stratified by each candidate variant genotype. Models were adjusted for the covariates 251 
listed above. Associations were examined for all NHL combined and by NHL subtype.  252 
Sensitivity analysis and multiple comparisons: All genetic data were assessed for 253 
deviations from allele frequencies expected under Hardy-Weinberg equilibrium among 254 
controls, and a sensitivity analysis was conducted in which we excluded study centers 255 
from the analysis of the specific genetic variants for which within-center allele 256 
frequencies were inconsistent with Hardy-Weinberg equilibrium at p<0.05. Additional 257 
sensitivity analyses were conducted excluding studies using clinic-based control 258 





All statistical tests were two-sided. For genetic analyses, the pACT statistic was 260 
used to account for multiple comparisons and correlated tests from variants within the 261 
same region [50]. Uncorrected p-values are reported in tables. For those associations 262 
with uncorrected p-values <0.05, pACT statistics are noted in the text. Statistical analysis 263 
was performed using Stata, version 13 (StataCorp, LP, College Station, TX). 264 
 265 
Results 266 
Main NHL associations 267 
7926 NHL patients and 10018 controls from 12 InterLymph studies met the 268 
inclusion criteria. The distribution of NHL patients and controls by selected demographic 269 
and clinical characteristics is shown in Table 1. The majority (83%) of patients were 270 
diagnosed with mature B-cell lymphoma (Table 2); the remainder were diagnosed with 271 
mature T-cell (6%), precursor cell (1%), and missing subtype/not otherwise specified 272 
(NOS) lymphomas (10%).  273 
Analysis with SNAP indicated candidate risk variants in IL1B (r2IL1B: rs16944, 274 
rs1143627=0.96) and in IL6 (r2IL6: rs1800795, rs1800797=0.97) were in high LD, and candidate 275 
variants in IL10 were in moderate LD (r2IL10: rs1800890, rs1800896=0.66).  276 
After adjustment for multiple comparisons, we observed strong main effects for 277 
associations between HLA variants and NHL (pACT<0.001 and pACT=0.004) and an 278 
IL1RN variant and NHL (pACT=0.04) (Supplemental Table 2). A history of IM was 279 
associated with all NHL combined (pBon=0.06) and strongly associated with CLL/SLL 280 
(pBon=0.04) and MCL (pBon=0.01) (Supplemental Table 3). The direction of the 281 
association between IM and NHL risk was consistent when restricted to population-282 





and IM for associations with all NHL and NHL subtypes were largely consistent with 284 
previously reported results from a subset of the same InterLymph studies [8, 9, 25, 28–285 
31].  286 
 287 
Gene-environment interaction in NHL risk 288 
There was an interaction effect between a genetic variant in the IL1B gene 289 
(rs1143627C) and IM history on TCL risk (ORinteraction=0.09, 95% CI=0.01, 0.87, p=0.04) 290 
risk. We also observed interaction between rs1800797A in the IL6 gene and IM on TCL 291 
risk (ORinteraction=0.08, 95% CI=0.01, 0.80, p=0.04) (Table 3). Neither of the associations 292 
persisted after adjustment for multiple comparisons (pACT>0.05). These results were 293 
directionally consistent when restricted to population-based case-control studies. 294 
Associations between IM history and T-cell lymphoma, stratified by IL1B and IL6 295 
genotypes, are shown in Supplemental Table 4. For each IL1B or IL6 variant, 296 
participants with the minor allele have a lower risk of NHL. However, effect estimates are 297 
unstable due to low sample sizes in strata comprised of IM-positive TCL patients. No 298 




IM was associated with an increased risk of TCL in the original main effects 303 
InterLymph paper [25] and with a 32% (p=0.17) increased risk among our subset of 304 
InterLymph participants. The minor allele in variant rs1143627 in the promoter region of 305 





in variant rs1800797 in the promoter region of the IL6 gene, although the interaction 307 
effects for both variants did not persist after adjustment for multiple comparisons.  308 
 IL-1B, the cytokine encoded by the IL1B gene, is an inflammatory response and 309 
fever mediator, and contributes to several lymphocyte activities including growth and 310 
differentiation of B-cells [51], proliferation of T-helper Type 2 (Th2) clones [52], and 311 
activation of Th17 cells [53]. We observed a suggestive interaction effect of similar 312 
magnitude between rs16944, an IL1B variant highly correlated with rs1143627, and 313 
TCL. IL1B is required for T-cell activation in some immune responses [54, 55] and thus 314 
could contribute to increased T-cell replication. The minor alleles of the two IL1B 315 
variants examined in our study are associated with lower expression of IL1B [56] and 316 
may decrease T-cell activation in the setting of IM. This decrease in activation may, in 317 
turn, attenuate the effects of the amplified T-cell response in IM. rs16944 has also been 318 
associated with uncontrolled EBV replication in liver transplant patients, who later 319 
develop post-transplant lymphoproliferative disorder [57], suggesting a link between IL-320 
1B and dysfunctional control of EBV. There was also suggestive association between 321 
the functional variant rs1800797 in the IL6 gene promoter region and risk of TCL. 322 
Through complex interactions with nearby variants, rs1800797 regulates the gene that 323 
encodes the inflammatory cytokine IL6, which influences growth and differentiation of T-324 
cells, among many other immune functions [58, 59].  325 
In the presence of the significant T-cell expansion associated with IM, the 326 
identified variants in IL1B and IL6 may reduce the chances of T-cell cell proliferation and 327 
subsequent mutation or oncogenic rearrangement. These findings may extend to other 328 





during primary or reactivated viral infections. Follow-up of these observations in a 330 
targeted study is warranted because of the potential biological pathway.  331 
A limitation of our study is reliance on self-reported IM history, which could be 332 
affected by recall bias. However, IM is a severe and debilitating syndrome of relatively 333 
long duration, interrupting young adult life; therefore, it is unlikely that a participant would 334 
forget this experience.  335 
Although the results can be generalized to adults of European descent living in 336 
the United States and Europe, the limited number of ethnically diverse participants 337 
enrolled in these studies and the exclusion of HIV/AIDS-related lymphomas and post-338 
transplant lymphomas limits generalizability to other groups. Because NHL patients 339 
were recruited after the onset of disease, those with longer post-diagnosis survival times 340 
were more likely to enroll in the study and complete questionnaires. This ascertainment 341 
bias prevents us from generalizing to NHL patients with very short survival times, 342 
although rapid case ascertainment methods at individual study sites dampened the 343 
impact of this bias. In general, survival times for TCL patients are shorter than those for 344 
B-Cell lymphoma patients [60, 61]. Among our sample of TCL participants, the majority 345 
were diagnosed with peripheral T-cell (51%) or mycosis fungoides/Sézary syndrome 346 
(MF/SS, 33%). Survival times for these subtypes vary significantly depending on stage 347 
at presentation and disease-specific factors (e.g. level of skin involvement by patch or 348 
plaque in MF/SS) [62, 63]. The introduction of new treatments such as Rituximab during 349 
the recruitment window for our study may have had additional impact on the subtypes of 350 
NHL patients we were able to recruit for study inclusion. Follow-up analyses are 351 
warranted to determine whether the effect modification we identified applies to patients 352 





Furthermore, data from sites using clinic-based recruitment methods for enrolling 354 
controls are subject to Berkson’s bias since patient controls are likely to be sicker than 355 
the general population from which cases were ascertained. Many admitting conditions of 356 
clinic-based controls may have some immune component which can obscure the effect 357 
of immune-related genetic variants on NHL and IM. Results of sensitivity analyses 358 
excluding sites using clinic-based control recruitment were directionally consistent with 359 
results using the full dataset, indicating the effect of Berkson’s bias on our study results 360 
was minimal. 361 
Our study was underpowered to detect an interaction between uncommon 362 
variants and IM within rare NHL subtype strata after adjusting for multiple comparisons. 363 
For example, in order to achieve 80% power of detecting an interaction odds ratio of 364 
0.09 for rs1143627 at α=0.05 after accounting for multiple comparisons, we would have 365 
needed 518 genotyped TCL patients. Thus, even with the overall large numbers of 366 
cases and controls in the study, there was inadequate power to detect associations by 367 
subtype. 368 
In summary, this study was the first to explore possible interaction between 369 
immune response genotypes and IM history on NHL risk [64]. The results from our study 370 
may have broader implications for understanding how certain genotypes modulate the 371 
impact of various infectious agents on NHL etiology. The identified variants in IL1B and 372 
IL6 may influence T-cell activation, growth, and differentiation in the presence of the 373 
massive T-cell expansion associated with IM leading to decreased immune cell 374 
proliferation. Although we observed a possible interaction that affected the risk of a rare 375 
NHL subtype, our study was underpowered to overcome multiple comparisons. 376 
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Table 1: Demographic characteristics of non-Hodgkin lymphoma patients and controls 
     Controls (N=10,018)    NHL Patients (N=7,926) 
  Negative IM history  Positive IM History  Negative IM history  Positive IM History 
  N (%)  N (%)  N (%)  N (%) 
Study 
Center 
BC 604 (6%)  35 (7%)  566 (8%)  42 (10%) 
EpiLymph-Czech Republic 289 (3%)  8 (2%)  165 (2%)  5 (1%) 
EpiLymph-France 250 (3%)  5 (1%)  198 (3%)  3 (1%) 
EpiLymph-Germany 628 (7%)  21 (4%)  435 (6%)  18 (4%) 
EpiLymph-Ireland 198 (2%)  5 (1%)  116 (2%)  11 (3%) 
EpiLymph-Italy 331 (3%)  3 (1%)  177 (2%)  2 (0%) 
EpiLymph-Spain 603 (6%)  5 (1%)  418 (6%)  6 (1%) 
Mayo Clinic 1,014 (11%)  85 (16%)  779 (10%)  80 (20%) 
NCI-SEER 378 (4%)  25 (5%)  543 (7%)  48 (12%) 
Scale 2,830 (30%)  106 (20%)  2,653 (35%)  94 (23%) 
UCSF 1,752 (18%)  189 (36%)  946 (13%)  63 (15%) 
Yale 620 (7%)  34 (7%)  523 (7%)  35 (9%) 
             
SES a Low 3,282 (35%)  63 (12%)  3,037 (40%)  74 (18%) 
 Medium 3,169 (33%)  146 (28%)  2,400 (32%)  134 (33%) 
 High 3,046 (32%)  312 (60%)  2,082 (28%)  199 (49%) 
             
Birth 
order First/Only 3,318 (35%)  182 (35%)  2,555 (34%)  149 (37%) 
 2nd 2,412 (25%)  154 (30%)  1,781 (24%)  115 (28%) 
 3rd 1,278 (13%)  83 (16%)  1,031 (14%)  50 (12%) 
 4th 1,653 (17%)  57 (11%)  1,392 (19%)  40 (10%) 
 Missing 836 (9%)  45 (9%)  760 (10%)  53 (13%) 




0 394 (4%)  24 (5%)  255 (3%)  23 (6%) 
1 1,578 (17%)  110 (21%)  1,144 (15%)  71 (17%) 
2 2,147 (23%)  159 (31%)  1,603 (21%)  118 (29%) 
3 4,673 (49%)  189 (36%)  3,908 (52%)  153 (38%) 
Missing 705 (7%)  39 (7%)  609 (8%)  42 (10%) 
             
Sex Male 5,018 (53%)  260 (50%)  4,052 (54%)  186 (46%) 
 Female 4,479 (47%)  261 (50%)  3,467 (46%)  221 (54%) 


















Age at NHL Diagnosis/Interview 57 ± 15 60 (21)   46 ± 15 47 (22)   60 ± 12 62 (17)   52 ± 13 53 (19) 
IM: infectious mononucleosis; IQR: interquartile range; SD: standard deviation; SES: socioeconomic status 
a Socioeconomic status (SES) was categorized based on years of education (low: 0-12 years, high school or less; medium: 13-15 years, some 




Table 2: Subtypes among non-Hodgkin lymphoma patients 
    N (%) 
B-cell DLBCL 2246  (28%) 
 CLL/SLL/B-PLL/MCL 1470  (19%) 
 Follicular 1691  (21%) 
 MZL 447  (6%) 
 MCL 325  (4%) 
 LPL/Waldenstrom 228  (3%) 
 Hairy cell 75  (1%) 
 Burkitt 63  (1%) 
 Precursor B-cell 40  (1%) 
 Burkitt-like 27  (0.3%) 
 B-Cell NOS 534  (7%) 
 TOTAL B-Cell 7146  (90%) 
    
T-Cell Peripheral T-cell 262  (3%) 
 MF/SS 166  (2%) 
 Precursor T-cell 26  (0.3%) 
 Nasal NK 17  (0.2%) 
 Large granular 7  (0.1%) 
 T-PLL 4  (0.1%) 
 T-Cell NOS 27  (0.3%) 
 TOTAL T-Cell 509  (6%) 
    
NOS a  210  (3%) 
Missing a   61  (1%) 
B-PLL: B-cell prolymphocytic leukemia; CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse 
large B-cell lymphoma; FL: follicular lymphoma; LPL: lymphoplasmacytic lymphoma; MCL: mantle cell lymphoma; MF/SS: 
mycosis fungoides/Sézary syndrome; MZL: marginal zone lymphoma; NK: natural killer cell; NOS: not otherwise specified; T-PLL: 
T-cell prolymphocytic leukemia; 







Table 3: Interaction between history of infectious mononucleosis and candidate risk variants [IL1A (rs1800587), IL1B 
(rs16944, rs1143627), IL1RN (rs454078), IL2 (rs2069762), IL6 (rs1800795, rs1800797), IL10 (rs1800896, rs1800890), TNFA 
(rs1800629), HLA I (rs6457327), and HLA II (rs10484561)] on risk of non-Hodgkin lymphoma by subtype: empirical-Bayes 













p-value b Variant N N 
All NHL IL1A-889C>T (rs1800587) 2,317 2,084 1.13 [0.69, 1.87] 0.62 
 IL1B-511C>T (rs16944) 1,280 1,311 0.66 [0.35, 1.22] 0.18 
 IL1B-31T>C (rs1143627) 3,715 3,130 0.76 [0.57, 1.02] 0.06 
 IL1RN-9589A>T (rs454078) 2,319 2,068 1.02 [0.62, 1.67] 0.94 
 IL2–384T>G (rs2069762) 2,320 2,080 0.99 [0.62, 1.57] 0.96 
 IL6-174G>C (rs1800795) 2,347 2,099 1.08 [0.77, 1.52] 0.64 
 IL6-597G>A (rs1800797) 3,852 3,304 1.10 [0.81, 1.49] 0.55 
 IL10-1082A>G (rs1800896) 4,173 3,472 0.81 [0.59, 1.10] 0.18 
 IL10-3575T>A (rs1800890) 5,914 5,629 0.80 [0.57, 1.13] 0.21 
 TNF-308G>A (rs1800629) 5,562 5,546 0.86 [0.59, 1.27] 0.46 
 HLA: C>A (rs6457327) 2,963 2,457 1.07 [0.65, 1.76] 0.78 
 HLA: T>G (rs10484561) 3,989 3,176 0.93 [0.62, 1.40] 0.74 
       
CLL/SLL IL1A-889C>T (rs1800587) 2,317 366 1.03 [0.45, 2.35] 0.95 
 IL1B-511C>T (rs16944) 1,280 117 1.30 [0.22, 7.56] 0.77 
 IL1B-31T>C (rs1143627) 3,715 646 0.96 [0.49, 1.87] 0.90 
 IL1RN-9589A>T (rs454078) 2,319 364 1.81 [0.80, 4.07] 0.15 
 IL2–384T>G (rs2069762) 2,320 365 1.77 [0.79, 3.98] 0.17 
 IL6-174G>C (rs1800795) 2,347 364 1.13 [0.49, 2.57] 0.78 
 IL6-597G>A (rs1800797) 3,852 666 0.89 [0.45, 1.76] 0.73 
 IL10-1082A>G (rs1800896) 4,173 669 0.80 [0.39, 1.62] 0.53 
 IL10-3575T>A (rs1800890) 5,914 1,204 0.68 [0.37, 1.24] 0.21 
 TNF-308G>A (rs1800629) 5,562 1,186 0.89 [0.47, 1.71] 0.73 
 HLA: C>A (rs6457327) 2,963 389 1.05 [0.36, 3.02] 0.93 
 HLA: T>G (rs10484561) 3,989 623 0.54 [0.20, 1.50] 0.24 
       
DLBCL IL1A-889C>T (rs1800587) 2,317 541 0.98 [0.48, 2.01] 0.96 
 IL1B-511C>T (rs16944) 1,280 384 0.75 [0.34, 1.68] 0.49 
 IL1B-31T>C (rs1143627) 3,715 877 0.61 [0.34, 1.08] 0.09 
 IL1RN-9589A>T (rs454078) 2,319 530 0.83 [0.41, 1.68] 0.61 
 IL2–384T>G (rs2069762) 2,320 538 2.02 [0.99, 4.13] 0.05 
 IL6-174G>C (rs1800795) 2,347 537 0.83 [0.43, 1.60] 0.59 
 IL6-597G>A (rs1800797) 3,852 922 0.92 [0.52, 1.64] 0.78 
 IL10-1082A>G (rs1800896) 4,173 928 1.10 [0.58, 2.09] 0.78 
 IL10-3575T>A (rs1800890) 5,914 1,496 0.74 [0.45, 1.21] 0.23 
 TNF-308G>A (rs1800629) 5,562 1,447 0.72 [0.42, 1.23] 0.23 
 HLA: C>A (rs6457327) 2,963 701 0.66 [0.32, 1.37] 0.26 
 HLA: T>G (rs10484561) 3,989 840 1.05 [0.51, 2.17] 0.89 
       
FL IL1A-889C>T (rs1800587) 2,317 527 1.18 [0.58, 2.41] 0.64 
 IL1B-511C>T (rs16944) 1,280 331 0.53 [0.20, 1.36] 0.19 
 IL1B-31T>C (rs1143627) 3,715 706 0.98 [0.54, 1.77] 0.95 
 IL1RN-9589A>T (rs454078) 2,319 526 0.63 [0.31, 1.29] 0.21 
 IL2–384T>G (rs2069762) 2,320 528 0.69 [0.35, 1.35] 0.28 
 IL6-174G>C (rs1800795) 2,347 533 1.34 [0.69, 2.60] 0.39 
 IL6-597G>A (rs1800797) 3,852 757 1.78 [0.94, 3.39] 0.08 
 IL10-1082A>G (rs1800896) 4,173 750 0.67 [0.37, 1.20] 0.18 
 IL10-3575T>A (rs1800890) 5,914 1,125 0.89 [0.51, 1.54] 0.68 
 TNF-308G>A (rs1800629) 5,562 1,130 0.91 [0.50, 1.65] 0.75 
 HLA: C>A (rs6457327) 2,963 510 1.65 [0.72, 3.79] 0.24 
 
 HLA: T>G (rs10484561) 3,989 696 0.86 [0.46, 1.62] 0.64 
       
MCL IL1A-889C>T (rs1800587) 2,317 103 2.24 [0.48, 10.33] 0.30 
 IL1B-511C>T (rs16944) 1,280 61 0.25 [0.02, 3.07] 0.28 
 IL1B-31T>C (rs1143627) 3,715 146 1.35 [0.33, 5.57] 0.68 
 IL1RN-9589A>T (rs454078) 2,319 102 1.24 [0.28, 5.53] 0.78 
 IL2–384T>G (rs2069762) 2,320 103 0.74 [0.16, 3.43] 0.70 
 IL6-174G>C (rs1800795) 2,347 105 0.28 [0.06, 1.24] 0.09 
 IL6-597G>A (rs1800797) 3,852 159 0.29 [0.08, 1.11] 0.07 
 IL10-1082A>G (rs1800896) 4,173 171 0.70 [0.15, 3.22] 0.64 
 IL10-3575T>A (rs1800890) 5,914 285 0.59 [0.20, 1.77] 0.35 
 TNF-308G>A (rs1800629) 5,562 279 3.27 [1.06, 10.05] 0.04 
 HLA: C>A (rs6457327) 2,963 116 2.75 [0.34, 22.05] 0.34 
 HLA: T>G (rs10484561) 3,989 158 0.29 [0.04, 2.33] 0.24 
       
T-Cell IL1A-889C>T (rs1800587) 2,317 127 2.76 [0.36, 21.42] 0.33 
 IL1B-511C>T (rs16944) 1,280 97 0.01 [0.00, 2.55] 0.10 
 IL1B-31T>C (rs1143627) 3,715 206 0.09 [0.01, 0.87] 0.04 
 IL1RN-9589A>T (rs454078) 2,319 125 0.37 [0.05, 2.75] 0.33 
 IL2–384T>G (rs2069762) 2,320 127 0.71 [0.12, 4.36] 0.71 
 IL6-174G>C (rs1800795) 2,347 129 0.05 [0.00, 1.01] 0.05 
 IL6-597G>A (rs1800797) 3,852 219 0.08 [0.01, 0.80] 0.03 
 IL10-1082A>G (rs1800896) 4,173 233 0.89 [0.16, 5.04] 0.90 
 IL10-3575T>A (rs1800890) 5,914 378 1.07 [0.36, 3.16] 0.91 
 TNF-308G>A (rs1800629) 5,562 369 1.20 [0.39, 3.71] 0.75 
 HLA: C>A (rs6457327) 2,963 183 3.36 [0.48, 23.47] 0.22 
  HLA: T>G (rs10484561) 3,989 210 1.82 [0.31, 10.58] 0.50 
CI: confidence interval; CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell 
lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; OR: odds ratio. 
a Interaction ORs, CIs, and p-values calculated using empirical-Bayes method adjusted for age, sex, study center, and 
socioeconomic status. 
b Significant values are shown in bold but did not retain significance after accounting for multiple comparisons using pACT 
statistic.   
 
 
